Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …

Acute coronary syndromes (ACS) are a comprehensive disease concept characterized by
acute myocardial ischemia caused by disruption of coronary artery plaque and consequent …

In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …

Summary Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is
recommended for up to 1 year in patients with acute coronary syndrome receiving …

Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …

Background: Owing to the differential propensity for bleeding and ischemic events with
response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor …

Background: Few data on the relative efficacy and safety of new P2Y 12 inhibitors such as
prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute …

Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …

Background Prediction of thrombotic and bleeding risk is important to optimize
antithrombotic therapy after percutaneous coronary intervention. Methods and Results We …